Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Bünyamin KISACIK"'
Publikováno v:
Volume: 9, Issue: 3 370-374
Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
CBU-SBED: Celal Bayar University-Health Sciences Institute Journal
Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
CBU-SBED: Celal Bayar University-Health Sciences Institute Journal
Objective: Paraneoplastic arthritis may mimic many rheumatic diseases. In case reports and studies published to date, RF and anti-CCP have been studied as markers in differentiating paraneoplastic arthritis from other rheumatic disease. Although thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6756acfe2455f1faedd143d5013e89b7
https://dergipark.org.tr/tr/pub/cbusbed/issue/72808/1033413
https://dergipark.org.tr/tr/pub/cbusbed/issue/72808/1033413
Autor:
Yüksel MARAŞ, Ali AKDOĞAN, Bünyamin KISACIK, Levent KILIÇ, Engin YILMAZ, Abdurrahman TUFAN, Umut KALYONCU, Şaziye Şule APRAŞ BİLGEN, Sedat KİRAZ, Ali İhsan ERTENLİ, Meral ÇALGÜNERİ
Publikováno v:
Volume: 44, Issue: 2 203-207
Turkish Journal of Medical Sciences
Turkish Journal of Medical Sciences
To define the frequency of familial Mediterranean fever gene (MEFV) mutations in ankylosing spondylitis (AS) and describe different clinical aspects of MEFV mutation carrier and noncarrier AS patients. Materials and methods: In 112 AS patients, Bath
Publikováno v:
European Journal of Rheumatology, Vol 9, Iss 2, Pp 111-113 (2022)
Externí odkaz:
https://doaj.org/article/e8c36b2b340c4451a0a3180aba88d605
Autor:
Mehmet Solakhan, Bünyamin Kısacık
Publikováno v:
European Journal of Rheumatology, Vol 8, Iss 1, Pp 27-30 (2021)
Externí odkaz:
https://doaj.org/article/4598341191ce4b32ac2b6469391fd837
Autor:
Şule Yaşar Bilge, Dilek Solmaz, Soner Şenel, Hakan Emmungil, Levent Kılıç, Sibel Yılmaz Öner, Fatih Yıldız, Sedat Yılmaz, Duygu Ersözlü Bozkırlı, Müge Aydın Tufan, Sema Yılmaz, Veli Yazısız, Yavuz Pehlivan, Cemal Beş, Gözde Yıldırım Çetin, Şükran Erten, Emel Gönüllü, Fezan Şahin, Servet Akar, Kenan Aksu, Umut Kalyoncu, Haner Direskeneli, Eren Erken, Bünyamın Kısacık, Mehmet Sayarlıoğlu, Muhammed Çınar, Timuçin Kaşifoğlu, İsmail Sarı
Publikováno v:
European Journal of Rheumatology, Vol 6, Iss 1, Pp 34-37 (2019)
Externí odkaz:
https://doaj.org/article/95fb34ac55224bda8142be050107ddc5
Existe uma relação entre a artrite gotosa e as mutações genéticas da febre familiar do Mediterrâneo?
Autor:
Ismail Sari, Ismail Simsek, Yusuf Tunca, Bunyamin Kisacik, Hakan Erdem, Salih Pay, Hasan Fatih Cay, Davut Gul, Ayhan Dinc
Publikováno v:
Revista Brasileira de Reumatologia, Vol 55, Iss 4, Pp 325-329 (2015)
RESUMOObjetivoA artrite gostosa e a febre familiar do Mediterrâneo (FFM) compartilham algumas características clínicas e patológicas, como ser classificada como uma doença autoimune inflamatória, ter associação com o inflamassoma, manifestar
Externí odkaz:
https://doaj.org/article/b9d3691fa52d4890b9005de310c7f56f
Autor:
Gozde Yildirim Cetin, Ayse Balkarli, Ali Nuri Öksüz, Gezmiş Kimyon, Yavuz Pehlivan, Ozlem Orhan, Bunyamin Kisacik, Veli Cobankara, Hayriye Sayarlioglu, Ahmet Mesut Onat, Mehmet Sayarlioglu
Publikováno v:
Revista Brasileira de Reumatologia, Vol 54, Iss 5, Pp 356-359 (2014)
Introdução: Colchicina é a viga-mestra para o tratamento de FFM, que é uma doença autoinflamatória com polisserosite recidivante como principal manifestação. Apesar de doses diárias de 2 mg ou mais/dia, aproximadamente 5%-10% dos pacientes c
Externí odkaz:
https://doaj.org/article/bd321be67fa8491c8874e6d321059a30
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Orhan Zengin, Mustafa Erkut Onder, Samet Alkan, Gezmiş Kimyon, Nergis Hüseynova, Zeynep Hanım Demir, Bünyamin Kısacık, Ahmet Mesut Onat
Publikováno v:
Revista Brasileira de Reumatologia, Vol 57, Iss 6, Pp 590-595
Abstract Anti-tumor necrosis factor drugs are frequently preferred in the treatment of rheumatologic diseases and other inflammatory diseases. The development of myositis after using anti-tumor necrosis factor drugs is a rare clinical condition. Here
Externí odkaz:
https://doaj.org/article/c5ada29b46794506b9664ed529015c2e